Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.55 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661200 | 0.88 | HDAC2 (0.61) | HDAC2HDAC1HDAC3HDAC10HDAC8 | |
| SCHEMBL3664385 | 0.87 | HDAC1 (0.53) | HDAC2MCHR1HDAC1BRD4JAK1 | |
| SCHEMBL3662008 | 0.87 | HDAC2 (0.64) | HDAC2HDAC1HDAC3HDAC10HDAC8 | |
| SCHEMBL3664654 | 0.86 | HDAC1 (0.53) | HDAC2MCHR1HDAC1BRD4JAK1 | |
| SCHEMBL3661211 | 0.85 | HDAC2 (0.75) | HDAC2HDAC1HDAC3HDAC10HDAC8 | |
| SCHEMBL3666016 | 0.85 | HDAC2 (0.59) | HDAC2MCHR1HDAC1HDAC3HDAC10 | |
| SCHEMBL3660370 | 0.84 | MCHR1 (0.53) | HDAC2MCHR1HDAC1BRD4JAK1 | |
| SCHEMBL3662573 | 0.83 | HDAC2 (0.62) | HDAC2HDAC1HDAC3HDAC10HDAC8 | |
| SCHEMBL3661299 | 0.82 | HDAC2 (0.74) | HDAC2HDAC1HDAC3HDAC10HDAC8 | |
| SCHEMBL3660109 | 0.82 | HDAC1 (0.55) | HDAC2MCHR1HDAC1BRD4JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | claimed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | claimed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | claimed |
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| EP-2220066-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | Gilead Colorado, Inc. (US) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009079391-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | GILEAD COLORADO, INC. (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292320-A1 | BENZOFURAN ANILIDE HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC7, HDAC5 | HDAC2 4/4885MCHR1 4638/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.